{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["115"],"submitter":["Wong YC"],"pubmed_abstract":["Background
Inducing T cell responses by vaccines among elderly has been a long-standing challenge. There is a need for effective COVID-19 vaccines to boost waning immunity against emerging SARS-CoV-2 variants, especially for the elderly. This study investigated the safety and immunogenicity of a PD-1-enhanced COVID-19 DNA vaccine (ICCOV™), as a booster vaccine in healthy adults (aged 18-59 years) and elderly (aged 60-75 years).Methods
This open-label, non-randomised Phase 2 study enrolled healthy participants aged 18-75 years who had previously been vaccinated with Sinovac CoronaVac, Pfizer-bioNTech Comirnaty vaccines, or both. Participants were stratified into four cohorts according to age, primary vaccination, and COVID-19 infection history, namely Adult-CoronaVac, Adult-"],"journal":["EBioMedicine"],"pagination":["105699"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12143208"],"repository":["biostudies-literature"],"pubmed_title":["An open-label study on the safety and immunogenicity of a PD-1-enhanced DNA vaccine used as a T cell booster for COVID-19."],"pmcid":["PMC12143208"],"pubmed_authors":["Woo KF","Jin X","Cheng WY","Tai WK","Zhou R","Du Y","Ngai Hung IF","Zhang R","Hang Ho DH","Chen Z","Polly Pang KP","Wang T","Wong YC"],"additional_accession":[]},"is_claimable":false,"name":"An open-label study on the safety and immunogenicity of a PD-1-enhanced DNA vaccine used as a T cell booster for COVID-19.","description":"Background
Inducing T cell responses by vaccines among elderly has been a long-standing challenge. There is a need for effective COVID-19 vaccines to boost waning immunity against emerging SARS-CoV-2 variants, especially for the elderly. This study investigated the safety and immunogenicity of a PD-1-enhanced COVID-19 DNA vaccine (ICCOV™), as a booster vaccine in healthy adults (aged 18-59 years) and elderly (aged 60-75 years).Methods
This open-label, non-randomised Phase 2 study enrolled healthy participants aged 18-75 years who had previously been vaccinated with Sinovac CoronaVac, Pfizer-bioNTech Comirnaty vaccines, or both. Participants were stratified into four cohorts according to age, primary vaccination, and COVID-19 infection history, namely Adult-CoronaVac, Adult-","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-01T12:07:32.518Z","creation":"2025-08-14T03:05:50.146Z"},"accession":"S-EPMC12143208","cross_references":{"pubmed":["40245494"],"doi":["10.1016/j.ebiom.2025.105699"]}}